Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations, OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER (Purdue), now include claims of abuse deterrence in their package inserts.
No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of abuse. Abuse-deterrent formulations have one or more properties that make their intentional nontherapeutic use more difficult, less attractive, or less rewarding; examples of such properties are listed in the Box.1
Abuse-Deterrent Opioid Formulations. JAMA. 2015;314(16):1744–1745. doi:10.1001/jama.2015.12869
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: